<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613479</url>
  </required_header>
  <id_info>
    <org_study_id>Inflammatory bowel disease</org_study_id>
    <nct_id>NCT04613479</nct_id>
  </id_info>
  <brief_title>Frequency of Hepatobilliary Manifestations in Patients With Inflammatory Bowel Disease</brief_title>
  <official_title>Frequency of Hepatobilliary Manifestations in Patients With Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatobilliary manifestations as extraintestinal manifestations of IBD are sometimes&#xD;
      underdiagnosed which can impair patient prognosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non alcoholic fatty liver is aliver disease most commonly found in patient with IBD most&#xD;
      commonly without intestinal activity.&#xD;
&#xD;
      On the other hand primary according cholangitis is the most common specific with IBD commonly&#xD;
      with ulcerative colitis. and is commonly overlap with autoimmune hepatitis IBD therapy can&#xD;
      also be a cause it can lead to hepatic toxicity and some drugs like ant TNF can cause&#xD;
      hepatitis b virus activation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The prevelance of hepatobilliary manifestations in IBD patients</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatobilliary Manifestations in Inflammatory Bowel Disease Patients</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients diagnosed IBD either crohns or ulcerative, male or female, age above 18 years&#xD;
        old.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:all patients diagnosed IBD crohns and ulcerative on conventional&#xD;
        treatment and biological treatment -&#xD;
&#xD;
        Exclusion Criteria:no&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hussein Elamin</last_name>
    <phone>01004084187</phone>
    <email>sehshammam@gmail.com</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hayam Fathy Nasr</investigator_full_name>
    <investigator_title>clinical doctor internal medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

